Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cell determination

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    589 result(s) found for: Cell determination. Displaying page 1 of 30.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-001393-19 Sponsor Protocol Number: 003:TCELL Start Date*: 2014-04-08
    Sponsor Name:Uppsala university
    Full Title: CD19-targeting 3rd generation CAR T cells for refractory B cell malignancy - a phase I/IIa trial.
    Medical condition: CD19+ B cell lymphoma or leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004043-36 Sponsor Protocol Number: 004:TCELL Start Date*: 2017-04-28
    Sponsor Name:Uppsala University
    Full Title: CD19-TARGETING 3RD GENERATION CAR T CELLS FOR REFRACTORY B CELL MALIGNANCY – A PHASE II TRIAL
    Medical condition: CD19+ B cell lymphoma or leukemia
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003298-28 Sponsor Protocol Number: M06-822 Start Date*: 2007-05-23
    Sponsor Name:Abbott Laboratories Limited (Queenborough, Kent, ME11 5EL, England)
    Full Title: A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Small Cell Lung Cancer (SCLC) or other non-hematological malignancies.
    Medical condition: Small cell lung carcinoma (SCLC) (North America or UK) and other non-hematological malignancies (North America only).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10041067 Small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004790-25 Sponsor Protocol Number: FD-BZK Start Date*: 2007-12-12
    Sponsor Name:University of Leipzig
    Full Title: Evaluation of the benefit of fluorescence diagnostics using Metvix® and the Dyaderm system for the preoperational estimation of the lateral tumour spread in basal cell carcinomas.
    Medical condition: basal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004146 Basal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000253-27 Sponsor Protocol Number: Pelle-926-301E Start Date*: 2020-06-05
    Sponsor Name:PellePharm, Inc.
    Full Title: A Phase 3, Multicenter, Open-Label Extension Study of Patidegib Topical Gel, 2% in Subjects with Gorlin Syndrome (Basal Cell Nevus Syndrome)
    Medical condition: Basal cell carcinomas (BCCs) in patients with Gorlin syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10004151 Basal cell nevus syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006694-24 Sponsor Protocol Number: IV-A05-LL-01-PR.03 Start Date*: 2007-07-16
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Phase I/II dose-escalation study of the investigational trifunctional bispecific anti-CD20 x anti-CD3 antibody FBTA05 in relapsed or refractory chronic lymphocytic leukemia
    Medical condition: relapsed or refractory Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-020408-31 Sponsor Protocol Number: I2I-MC-JMMG Start Date*: 2010-11-10
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination with Pemetrexed and Cisplatin in Patients with Stage IV Non-small Cell Lung Cancer
    Medical condition: • Histological diagnosis of Stage IV NSCLC other than predominantly squamous cell histology. • Mesothelioma in advanced or metastatic stage for whom the combination with pemetrexed and cisplatin i...
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002143-25 Sponsor Protocol Number: M06-873 Start Date*: 2008-11-11
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia.
    Medical condition: Relapsed or Refractory Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008978 Chronic lymphocytic leukemia refractory LLT
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001456-29 Sponsor Protocol Number: Mino-TRD(OptiMD) Start Date*: 2015-09-23
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: A Double-blind, Placebo-controlled, Randomized, Multicenter Proof-of-principle Trial of Adjunctive Minocycline for Patients With Treatment Resistant Unipolar Major Depressive Disorder (MDD)
    Medical condition: Minocycline, a broad-spectrum and central nervous system entering tetracycline, reduces within an additional therapy the symptomatology of depressive patients.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003039-65 Sponsor Protocol Number: P30-120 Start Date*: 2008-06-03
    Sponsor Name:Alfacell Corporation
    Full Title: A phase I / II trial of intravenous Onconase(R) in subjects with non-small cell lung cancer
    Medical condition: Non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029521 Non-small cell lung cancer stage IIIB LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001951-20 Sponsor Protocol Number: UCL/06/053 Start Date*: 2008-03-12
    Sponsor Name:University College London
    Full Title: A phase I and randomised phase II study of Docetaxel and RAD001 (Everolimus) in advanced/recurrent or metastatic squamous cell carcinoma of the head and neck
    Medical condition: Locally advanced or metastatic squamous cell carcinoma of the head and neck
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063569 Metastatic squamous cell carcinoma LLT
    9.1 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002373-59 Sponsor Protocol Number: 19-00153 Start Date*: 2020-12-22
    Sponsor Name:University Medical Center of the Johannes Gutenberg University Mainz
    Full Title: A prospective, multicenter phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients with relapsed/refractory transformed or Aggressive Lymphoma (GOAL II).
    Medical condition: Malignant B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003903 B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001339-33 Sponsor Protocol Number: SCITVITD3 Start Date*: 2018-07-05
    Sponsor Name:Academisch medisch centrum Amsterdam
    Full Title: A randomized, double-blind, placebo-controlled, study to determine the added value of vitamin D3 to treatment with subcutaneous immunotherapy in patients with moderate to severe allergic rhinitis/ ...
    Medical condition: subcutaneous immunotherapy in allergic rhinitis (AR) patients with allergies to birchpollen
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002409-23 Sponsor Protocol Number: CLN-081-001(REZILIENT1) Start Date*: 2020-02-27
    Sponsor Name:Cullinan Oncology Inc.
    Full Title: A Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients with Locally-Advanced or Metastatic Non-Small C...
    Medical condition: Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004628-31 Sponsor Protocol Number: FIL_V-RBAC Start Date*: 2018-05-15
    Sponsor Name:Fondazione Italiana Linfomi ONLUS
    Full Title: Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma (MCL)
    Medical condition: Mantle Cell Lymphoma in elderly patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10026799 Mantle cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-014641-88 Sponsor Protocol Number: STP-LYM-01-V01 Start Date*: 2010-01-14
    Sponsor Name:Medizinische Fakultaet der Technischen Universitaet Muenchen
    Full Title: Phase I/II dose-escalation study of the investigational trifunctional bispecific anti-CD20 x anti-CD3 antibody FBTA05 in combination with donor lymphocyte infusion (DLI) in patients with CD20 posit...
    Medical condition: CD20 positive chronic lymphocytic leukemia (CLL) low and high grade non-Hodgkin´s lymphoma (NHL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-001700-39 Sponsor Protocol Number: IP-REM-PK-01-EU Start Date*: 2005-09-14
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Determination of systemic exposure and characterization of pharmacokinetics of the tri-functional antibody catumaxomab (anti-EpCAM X anti-CD3) administered intraperitoneally in EpCAM positive cance...
    Medical condition: epithelial cell adhesion molecule (EpCAM) expressing tumors in patients with malignant ascites requiring therapeutic ascites puncture
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025538 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-007022-64 Sponsor Protocol Number: NMSG 16/07 Start Date*: 2007-03-06
    Sponsor Name:Rigshospitalet
    Full Title: Phase II study of bortezomib-dexametason and high-dose melphalan in patients relapsing after high-dose melphalan with autologous stem cell support
    Medical condition: Patients with multiple myeloma earlier treated with high-dose melphalan with autologous stem cell support experiencing their first relapse.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003658-22 Sponsor Protocol Number: XmAb13676-03 Start Date*: 2022-09-21
    Sponsor Name:Xencor, Inc.
    Full Title: A Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of XmAb®13676 (Plamotamab) Combined with Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide i...
    Medical condition: Relapsed or refractory diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10012820 Diffuse large B-cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023854-35 Sponsor Protocol Number: CD-ON-MEDI-575-1031 Start Date*: 2011-11-07
    Sponsor Name:MedImmune, LLC
    Full Title: A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Ce...
    Medical condition: Previously untreated advanced non-small cell lung cancer in adults
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Completed) BG (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 09 23:33:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA